

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A/PTC)		Complete if Known			
				Application Number	09/763,794		
-INFO	DRMATION-	DIS	CLOSURE	Filing Date	July 12, 2001		
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Jan SIMON		
				Group Art Unit	Unassigned (642		
	(use as many she	ets as	necessary)	Examiner Name	Unassigned C. Yasan		
Sheet	1	of	2	Attorney Docket Number	24741-1505		

U.S. PATENT DOCUMENTS						
Examiner Cite No.1		U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Releva
	Number Kind Code ² (if known)		of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
CY	A01	4,725,585		Wenge et al.	02-16-1988	
	ļ					
	ļ					
	 					

	Cite No.1	Foreign Patent Document			Name of Patentee or	Date of Publication	Pages, Columns, Lines,	
		Office ³		nd Code⁵ f known)	Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te
CY	A02	JP	64-000469		Chugai Pharmaceut Co Ltd	01-05-1989	Abstract	
cY	.A03	DE	44 12 794	A1	Klinikum der Albert-Ludwigs- Universitaet Freiburg	12-14-1995		·
CY	A04	JP	09-012600	1	Shiseido Co Ltd	01-14-1997	Abstract	
CY	A05	wo	97/12633	A1	Immunex Corporation	04-10-1997		
CY	A06	JP	09-229930		Seikagaku Kogyo Co Ltd	09-05-1997	Abstract	
CY	A07	wo	97/33592	A1	Hyal Pharmaceutical 09-18-1997 Corporation			
CY	A08	wo	98/13382	A1	Amrad Operations Pty. Ltd.	04-02-1998		
сү	A09	DE	198 02 540	C1	Klinikum der Albert-Ludwigs- Universitaet Freiburg	11-19-1998		

Examiner Signature	Chrusoh HY	Date Considered	1-29-03
0.9			•

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information of information of the contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known Application-Number--09/763-794 INFORMATION DISCLOSURE Filing Date July 12, 2001 STATEMENT BY APPLICANT First Named Inventor Jan SIMON Group Art Unit Unassigned (use as many sheets as necessary) **Examiner Name Unassigned** C. Yaen of 2 24741-1505 Sheet Attorney Docket Number

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2		
CY	A10	HAEGEL-KRONENBERGER, H. et al., "Regulation of CD44 Isoform Expression and CD44-Mediated Signaling in Human Dendritic Cells", Advances in Experimental Medicine and Biology, 1997, pp. 83-90, No. 417.			
CY	A11	TERMEER, C. et al., "Dendritic Cell (DC) Maturation by Small Fragments of Hyaluronan (HA) Involves a Highly Specific Nf-01κB and TNF01α-Dependent Pathway", Journal of Investigative Dermatology, Abstracts for the 60th Annual Meeting of the Society for Investigative Dermatology, May 5-9, 1999, pp. 579, Vol. 12, No. 4.			
<u> </u>					

Examiner Signature	Chrisp	MX	Date Considered	1-29-03
-----------------------	--------	----	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.